MBAPL H1 profit rises 89% despite 21% NPK/DAP volume fall
Key highlights
- MBAPL's H1 FY27 PAT rose 89% year on year to Rs 111 crore.
- H1 FY27 NPK/DAP sales fell 21% to 92,381 tons, while SSP sales rose 6% to 125,392 tons.
- MBAPL's Q2 FY27 EBITDA margin was 17.9%, compared with 13.7% in Q2 FY26.
- MBAPL reported Q2 FY27 NPK/DAP production of 47,807 tons at 58% utilisation.
powered by IRIS

MBAPL reported H1 FY27 PAT of Rs 111 crore, up 89% year on year, despite a 21% decline in NPK/DAP sales to 92,381 tons; revenue reached Rs 1,135 crore and EBITDA rose 66% to Rs 197 crore, although the presentation does not allocate earnings by product.
Know Madhya Bharat Agro Products inside out
Results, valuation, peers and who's buying, in one view.
How did MBAPL's H1 FY27 earnings change?
MBAPL's H1 FY27 revenue rose 32% year on year to Rs 1,135 crore, while EBITDA, or earnings before interest, tax, depreciation and amortisation, increased 66% to Rs 197 crore and PAT, or profit after tax, rose 89% to Rs 111 crore. Earnings per share increased to Rs 2.52 from Rs 1.34 in H1 FY26, also a reported 89% increase.
The Q2 FY27 result contributed Rs 715 crore of revenue, Rs 128 crore of EBITDA and Rs 78 crore of PAT to the first-half outcome. This compared with Q1 FY27 revenue of Rs 420 crore, EBITDA of Rs 69 crore and PAT of Rs 33 crore, and with Q2 FY26 figures of Rs 450 crore, Rs 62 crore and Rs 31 crore, respectively.
Margins were also higher in Q2 FY27 than in both comparison quarters. EBITDA margin was 17.9%, compared with 16.5% in Q1 FY27 and 13.7% in Q2 FY26, while PAT margin reached 10.9% from 7.9% and 6.8%, respectively; Q2 FY27 earnings per share were Rs 1.76 versus Rs 0.75 and Rs 0.70.
Why did MBAPL profit rise while NPK/DAP sales fell?
MBAPL does not disclose a product-level explanation for the Rs 52 crore increase in H1 PAT because it provides no revenue, realisation or profitability split between NPK/DAP and Single Super Phosphate, or SSP. NPK/DAP sales declined by 23,906 tons to 92,381 tons in H1 FY27, whereas SSP sales rose by 6,974 tons to 125,392 tons.
The reported sales pattern shows total revenue rising 32% even as NPK/DAP volume fell 21%, meaning group sales value did not track that volume measure alone. The 6% increase in SSP sales accompanied the result, but the presentation does not quantify how much SSP contributed to the rise in revenue, EBITDA or PAT.
Management said it intends to expand its NPK presence through a better and more profitable product mix, but did not disclose the H1 FY27 mix, prices or average realisations. It also said NPK and SSP price revisions, where implemented, partially offset higher raw-material costs, without specifying the revision amounts or their effect on the Rs 197 crore H1 EBITDA.
MBAPL's chairman cited supply-chain disruption, raw-material volatility and an uneven monsoon as conditions affecting Q2 FY27. Those factors provide context for operations, but the presentation does not identify an individual cause for the 21% decline in NPK/DAP sales or quantify subsidy receipts, procurement savings, freight costs or price-led gains.
Got a follow-up? Ask IRIS
What did MBAPL's Q2 production and utilisation show?
MBAPL's Q2 FY27 NPK/DAP production recovered from Q1 FY27 but remained below the prior-year quarter. Output was 47,807 tons at 58% utilisation, compared with 35,632 tons at 43% in Q1 FY27 and 56,207 tons at 94% in Q2 FY26.
SSP production moved in the other direction, falling to 53,088 tons in Q2 FY27 from 63,592 tons in Q1 FY27 and 62,334 tons in Q2 FY26. SSP utilisation was 37%, versus 45% and 104%, after the stated annual capacity increased from 240,000 tons to 570,000 tons from 30 March 2026.
Backward-integrated operations had mixed Q2 FY27 utilisation. Beneficated rock phosphate, or BRP, crushing reached 43,367 tons and 92% utilisation, up from 31,223 tons and 66% in Q1 FY27; phosphoric acid output rose to 7,227 tons at 42% from 5,332 tons at 31%. Sulphuric acid output fell to 13,199 tons at 10%, compared with 22,963 tons at 17% in Q1 FY27.
The presentation contains capacity figures that it does not reconcile. Its backward-integration overview lists annual NPK/DAP capacity of 660,000 tons and phosphoric acid capacity of 168,000 tons, while the Q2 utilisation snapshot uses 330,000 tons and 69,000 tons, respectively. This unresolved difference matters when assessing the reported 58% NPK/DAP and 42% phosphoric-acid utilisation rates.
What could affect MBAPL after H1 FY27?
MBAPL's chairman said new NPK/DAP and backward-integrated phosphoric-acid facilities at Dhule had been commissioned by Q2 FY27, with management now focused on production, capacity utilisation and operating efficiency. The disclosed Q2 FY27 utilisation levels of 58% for NPK/DAP and 37% for SSP provide the starting point for judging progress against that plan.
Management also pointed to the Government of India's approved 64% increase in Nutrient-Based Subsidy, or NBS, rates for the Rabi 2026-27 season, with a total outlay of Rs 62,370 crore. The chairman described support for nitrogen, phosphorus and sulphur as a policy tailwind for domestic phosphatic and complex-fertiliser production, but the presentation does not estimate the financial effect on MBAPL.
On raw materials, MBAPL disclosed a green-ammonia arrangement for 130,000 tons over 10 years, with an upper price limit and downward flexibility subject to contractual terms. Supplies are expected from April 2029; the company also cited long-term rock-phosphate sourcing from Egypt, Jordan and domestic suppliers, alongside multiple sulphur and sulphuric-acid suppliers.
Conclusion
MBAPL's H1 FY27 outcome combined revenue growth of 32%, EBITDA growth of 66% and PAT growth of 89% with lower NPK/DAP sales volumes. The available data establish that SSP sales increased and Q2 margins improved, but they do not establish how much of the profit increase came from product mix, price revisions, subsidies, input costs or backward integration.
The next disclosures should indicate whether NPK/DAP output rises beyond Q2 FY27's 47,807 tons and whether utilisation improves from 58% for NPK/DAP and 37% for SSP. Investors should also watch for a reconciliation of capacity figures, management's assessment of Rabi 2026-27 NBS effects, and progress toward green-ammonia supplies expected from April 2029.


